Bayer's finerenone approved in India for heart failure
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Tirzepatide is a prescription based the first and only dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
New study presents a human-relevant stress model for assessing potential therapeutics
Subscribe To Our Newsletter & Stay Updated